NCT03817736View on ClinicalTrials.gov

Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

June 14, 2022

Study Completion Date

July 26, 2023

Conditions
HCC
Interventions
PROCEDURE

TACE

Procedure of TACE will be standardized.

RADIATION

SBRT

SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.

DRUG

Immune Checkpoint Inhibitor

An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.

Trial Locations (1)

Unknown

Department of Clinical Oncology, Hong Kong

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

The University of Hong Kong

OTHER

NCT03817736 - Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy | Biotech Hunter | Biotech Hunter